Team — MolAIcule

×

Yongjin (Kevin) Hou

AI Technologist & Business Executive — Co-founder & CEO

AI-biotech entrepreneur leading platform strategy and translational partnerships.

Background

Co-founder & CEO of MolAIcule; extensive experience in AI-driven drug discovery and technology ventures.

Expertise

AI platform strategy and development
Translational partnerships & collaborations
Biotech business development
Cross-disciplinary leadership

Vision

Revolutionize drug discovery through agentic-AI molecular design and development.

×

Jianfeng Cai, PhD

Peptide & Medicinal Chemist — Co-founder

Distinguished peptide chemist; macrocycles, peptidomimetics, and drug-like scaffolds.

Background

Co-founder with deep expertise in peptide chemistry and medicinal chemistry.

Expertise

Peptide synthesis & modification
Macrocycle design & optimization
Peptidomimetic development
Drug-like scaffold engineering
SAR & property tuning

Focus

Innovative peptide-based therapeutics with enhanced stability, selectivity, and developability.

×

Hongjun Yang, PhD

Senior Scholar & Pharma Executive — Co-founder & Co-CEO

Cancer biologist focused on target validation, in vivo pharmacology, and translation.

Background

Co-founder with extensive experience bridging basic biology and clinical translation.

Expertise

Cancer target validation
In vivo pharmacology & toxicology
Translational strategy
Preclinical development
Regulatory pathways

Leadership

Advanced multiple therapeutics from discovery to clinical development.

×

Zhengping Zhuang, MD, PhD

Cancer Biology & Disease Researcher — Scientific Advisor

Clinician-scientist providing strategic guidance on indication strategy.

Background

Scientific Advisor with dual MD/PhD training in oncology and disease biology.

Expertise

Cancer biology & pathogenesis
Disease-mechanism elucidation
Clinical indication strategy
Patient-centered development
Translational medicine

Strategic Role

Guides indication selection, target validation, and clinical development strategy.

×

Webster Cavenee, PhD

Cancer Genetics Pioneer — Scientific Advisory Board Chair

Pioneering molecular geneticist; landmark work in oncogenic signaling & glioblastoma.

Background

Distinguished Professor, UC San Diego; former Director, Ludwig Institute for Cancer Research (San Diego) and Director of Strategic Alliances in CNS Cancers at Ludwig Cancer Research.

Honors & Societies

Elected Member, U.S. National Academy of Sciences & National Academy of Medicine
Foreign Member, German National Academy of Sciences Leopoldina & Chinese Academy of Engineering
Fellow, AAAS & American Association for Cancer Research; Member, ASCO & ASCI
Szent-Györgyi Prize for Progress in Cancer Research (NFCR)

Leadership

30+ years shaping cancer genetics and translational oncology; advisor to biopharma & academia on tumor biology, biomarkers, and therapeutic development.

×

Shen Xiao, MD, PhD

Clinical & Regulatory Leader — Medical & Regulatory Advisor

Physician-scientist & former FDA/CDER leader; global clinical development & regulatory strategy.

Experience

Chief Scientific Officer, Alebund Pharmaceuticals (2025– ) — portfolio strategy; end-to-end development & global regulatory
Chief Medical Officer, Hasten (2024–2025); CSO/CMO at 3D Medicines (2021–2024)
U.S. FDA/CDER (2002–2021) — Senior Medical Officer (prev. Medical Officer; Pharm/Tox Reviewer); IND/NDA/BLA leadership; cross-center cardio-renal safety & guidance

Honors

CDER Scientific Achievement Award; APS Excellence in Renal Research Award